Journal
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 23, Issue 1, Pages 133-144Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2008.09.003
Keywords
cannabinoids; anxiety; depression; Sativex; dronabinol; nabilone; rimonabant; taranabant
Categories
Funding
- Alexander von Humboldt Foundation (Germany)
Ask authors/readers for more resources
Both agonists (e.g. Delta(9)-tetrahydrocannabinol, nabilone) and antagonists (e.g. rimonabant, taranabant) of the cannabinoid type-1 (CB1) receptor have been explored as therapeutic agents in diverse fields of medicine Such as pain management and obesity with associated metabolic dysregulation, respectively. CB, receptors are widely distributed in the central nervous system and are involved in the modulation of emotion, stress and habituation responses, behaviours that are thought to be dysregulated in human psychiatric disorders. Accordingly, CB1 receptor activation may, in some cases, precipitate episodes of psychosis and panic, while its inhibition may lead to behaviours reminiscent of depression and anxiety-related disorders. The present review discusses these side-effects, which have to be taken into account in the therapeutic exploitation of the endocannabinoid system. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available